Sharpe

To translate recent advances in medical device interoperability research into clinical practice, standards are being developed that specify precise requirements towards the network representation of particular medical devices connecting through ISO/IEEE 11073 SDC. The present contribution supplements this protocol standard with specific models for…[Read more]

Early prediction of elimination pathways for new chemical entities can have a profound impact on drug discovery programs. The recently proposed Extended Clearance Classification System (ECCS) is a step in the right direction, providing a framework to help identify the major elimination pathway of a drug. A list of 42 Amgen small molecules was…[Read more]

9%) and ESUS (44% versus 34.7%), this difference did not reach significance after Bonferroni-adjustment for multiple comparisons (P> .05, each). There was no difference in the prevalence of an MTSP among subjects with known (n = 11/51; 21.6%) versus subsequently diagnosed (n = 1/3; 33.3%) AF (P= .54). CONCLUSIONS Our findings indicate that the kno…[Read more]

This study was focused on the development and validation of a Mid-IR based calibration model. The results indicate that surface a residue of 0.19 μg cm-2 for a specific molecule is detectable using a specular reflectance Mid-IR technique.The electrocatalytic hydrogen evolution reaction (HER) has attracted substantial attention owing to its…[Read more]

The accumulation of amyloid-β, a metabolic residue found in the brain, has been linked to cognitive ageing and Alzheimer’s disease. A longitudinal study reveals that the increase of amyloid-β can be predicted using simple sleep parameters.Dead museum specimens are finding new life, providing critical data about otherwise hidden impacts of h…[Read more]

Using the tumor growth rate, 90% of all patients showed a tumor reduction between first and final response evaluation. The 6-month, 1-, 2- and 3-year overall survival rates were 86.5%, 67.4%, 47.2%, and 33.7%, with a median survival of 45, 24, 15, and 14 months for complete response, partial response, stable disease, and progressive disease,…[Read more]